Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Epistemonikos ID: bbf95ed3b4f94404e9f81fa5d85888b68ace2b6f
First added on: Sep 19, 2025